[No advantage to using the CMF-regimen for node positive, postmenopausal, receptor-positive mammary carcinoma with adjuvant tamoxifen therapy].
Heidemann
E
E
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008207:Lymphatic Metastasis; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D017698:Postmenopause; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D013629:Tamoxifen / Q000008:administration & dosage*
D013629:Tamoxifen; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate
Kein Vorteil durch zusätzliche CMF-Behandlung bei nodal positivem, postmenopausalem, Rezeptor-positivem Mammakarzinom unter adjuvanter Tamoxifen-Therapie.